Recent News

Upcoming Seminars and Events

View upcoming seminars and events.

Learn more
553 News Items found
In Brief
MSK light bright image
Can You Hear Me Now? Scientists Find Nanoparticles Have a Language of Their Own

Nanoparticles were thought of a silent partner in imaging technologies. They’re now being recognized as an important source of subatomic chatter.
In the Clinic
Chemical biologist Gabriela Chiosis in a laboratory
Experimental Cancer Drug Developed at MSK Leads to New Approach for Treating Alzheimer's Disease

A family of drugs developed at MSK targets disrupted processes in cells in diseases related to aging.
In Brief
Illustration of girl standing in front of charging bull
Scientists Identify How Gene Mutation Drives a Deadly Childhood Cancer

Synovial sarcoma is an aggressive cancer primarily affecting children and young adults. A new study gets to the bottom of it.
In the Clinic
Man and woman in white lab coats looking at test tubes
Single-Cell Analysis Enables Researchers to Understand the Differences within Tumors

Scientists are decoding the genetic changes that drive individual cancer cells. This may help them develop more-effective targeted therapies.
In the Clinic
Jedd Wolchok and Charlotte Ariyan in the lab
Chemotherapy-Immunotherapy Combination Aims to Knock Out Melanoma with a One-Two Punch

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.
In the Clinic
Medical oncologist Jae Park
Longest-Running CAR T Trial Shows Which Patients Benefit Most, Have Fewest Side Effects

The study represents 20 years of research at MSK.
New Study Examines the Longest-Running CAR T Cell Trial and Finds Acute Lymphoblastic Leukemia Patients May Do Better When Treated Early

Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.  
In the Lab
abstract red and blue lines suggestive of metabolic pathways
Scientists Create First-of-Its-Kind Metabolic Road Map of Cancer

The online resource will serve as a benchmark for researchers studying metabolism and cancer.
Proof of Principle: Tri-Institutional Therapeutics Discovery Institute Drug Candidates “Graduate” to Next Phase of Development

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.
In the Lab
A gray blob marked RAS linked to colorful rods marked ICMT
Deciphering How Membrane Enzymes Work, with a Little Help from Beetles

The atomic structure of an elusive type of membrane protein has finally been solved by scientists at the Sloan Kettering Institute.